Page last updated: 2024-08-24
plerixafor and Adenocarcinoma of Lung
plerixafor has been researched along with Adenocarcinoma of Lung in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ge, D; Gu, J; Liu, Z; Lu, C; Mao, W; Shou, H; Xu, F; Zhang, K; Zhang, Z; Zhu, Q | 1 |
Other Studies
1 other study(ies) available for plerixafor and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Benzylamines; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclams; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Receptors, CXCR4; RNA, Small Interfering; Smad2 Protein; Transforming Growth Factor beta1; Up-Regulation | 2020 |